3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
3
Active not recruiting
2
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
19
Metastatic Castration-resistant Prostate Cancer
3
Prostatic Diseases
2
Urogenital Neoplasms
1
Renal Insufficiency
1
Prostate Cancer Metastatic
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasms by Site
1
Neoplasms
1
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
1
Male Urogenital Diseases
1
Liver Neoplasms
1
Glioma
1
Glioblastoma
1
Genital Neoplasms, Male
1
Genital Diseases, Male
1
Disease
1
Carcinoma, Hepatocellular
1
Astrocytoma
1
Interventions
darolutamide
3
Pluvicto
3
Docetaxel
3
testosterone 17 beta-cypionate
2
sipuleucel-T
1
lactitol
1
fludarabine phosphate
1
fludarabine
1
enzalutamide
1
ebastine
1
cabozantinib
1
cabazitaxel
1
Standard of Care
1
Prednisone
1
Prednisolone
1
PSMA-617
1
Gonadotropin-Releasing Hormone
1
Cyclophosphamide
1
Bortezomib
1
Blood Specimen Collection
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Metastatic Castration-resistant Prostate Cancer
×
Pluvicto
×
Clear all
NCT06866938
2026-01-06
ReaLuP
Hospices Civils de Lyon
Phase 2
Recruiting
58 enrolled
NCT06514521
2025-12-30
Post Marketing Study on Pluvicto in Korea
Novartis
Recruiting
278 enrolled
NCT05613894
2025-10-31
CaboLu
University of Utah
Phase 1
Recruiting
33 enrolled